FAQ: What is the importance of biomarkers such as fecal calprotectin and CRP?
Description
In this educational discussion, Mikhail Alper, PA-C, from Fresno, California, highlights the critical role of biomarkers like fecal calprotectin and C-reactive protein (CRP) in managing inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease. He explains how these biomarkers provide objective measures of inflammation and treatment response—often revealing more than patient-reported symptoms alone. Michael outlines a practical monitoring timeline, recommending assessment at six weeks to gauge early symptom improvement, followed by biomarker testing at 12 weeks, and endoscopic evaluation at six months to confirm mucosal healing. He also notes the growing value of intestinal ultrasound, though access remains limited in some regions. This video underscores why integrating biomarker monitoring into IBD management is essential for optimizing therapy and improving patient outcomes.
United States
